hrp 102 has been researched along with Weight Gain in 2 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 1 (50.00) | 18.2507 |
2000's | 1 (50.00) | 29.6817 |
2010's | 0 (0.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
el-Hussinie, M; el-Nahal, N; Hassan, EO | 1 |
Albrecht, G; Arboleda, C; Bailon, R; Bassol, S; Bucheli, R; Carneiro de Oliveira, H; Carranza, S; CastaƱeda, A; Celis, C; Chada, E; Cravioto, MC; de Andrade, ME; de Mello, NR; de Melo, K; Durand, M; Fugarolas, J; Gaona, R; Garza-Flores, J; Gomez, P; Gurucharri, C; Hidalgo, I; Lopez, C; Mendez, J; Novelli, J; Olavide, R; Parada, LM; Parejarios, J; Reyes-Marquez, R; Santoyo, S; Succar, J; Trujillo, L; Vazquez, L; Yassle, ME | 1 |
2 trial(s) available for hrp 102 and Weight Gain
Article | Year |
---|---|
Once-a-month injectable contraceptives, Cyclofem and Mesigyna, in Egypt. Efficacy, causes of discontinuation, and side effects.
Topics: Adult; Contraceptive Agents, Female; Contraceptives, Oral, Combined; Drug Administration Schedule; Drug Combinations; Egypt; Estradiol; Female; Humans; Injections, Intravenous; Medroxyprogesterone Acetate; Norethindrone; Patient Compliance; Weight Gain | 1999 |
Mesigyna once-a-month combined injectable contraceptive: experience in Latin America.
Topics: Adolescent; Adult; Amenorrhea; Blood Pressure; Contraceptive Agents, Female; Drug Combinations; Estradiol; Female; Humans; Injections; Latin America; Norethindrone; Pregnancy; Uterine Hemorrhage; Weight Gain | 2000 |